mCRPCmetastatic castration-resistant prostate cancerprostate cancermelanomaipilimumab
…s with mCRPC.Methods Data were analyzed from n=27 patients with mCRPC treated with ipilimumab in a single-center clinical trial ( NCT…
10articles mentioning diseases
13disease mentions
1distinct diseases extracted
0%of mentions human-reviewed
metastatic castration-resistant prostate cancer
This disease is selected. Its supporting articles are shown below.
Articles mentioning metastatic castration-resistant prostate cancer
10 articles · page 1 of 1metastatic castration-resistant prostate cancermCRPCpancreatic ductal carcinomaprostate canceripilimumabenzalutamideJ Clin OncolAtezolizumab
…al. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat Med. 2022;28:144–53.Koo KC, Pa…
prostate cancerMerkel cell carcinomasmall cell lung cancerbreast cancerneuroendocrine tumours
…-phase development to practice-changing trials, particularly in prostate cancer and neuroendocrine tumours. 51 In prostate cancer, the phase II…
mCRPCmetastatic castration-resistant prostate cancerpembrolizumabArm AArm BpTVG-HP
…ater anti-tumor efficacy.Materials and methods 60 patients with mCRPC were treated with vaccine on days 1 and 8 of a 3 week cycle, wi…
advanced prostate cancermCRPCmetastatic castration-resistant prostate cancerdurvalumabolaparibabirateroneenzalutamideNCT02484404
…e (PARP) inhibition (PARPi) is a precision medicine strategy in advanced prostate cancer, with the greatest benefit seen in a subset of patients with ho…
98.7%
metastatic castration-resistant prostate cancerLutatherainoperable or metastatic gastro-enteropancreatic neuroendocrine tumours177Lu-oxodotreotidePluvicto177Lu-PSMALutetium-177177Lu
…rmaceuticals such as Pluvicto (177Lu-PSMA) for the treatment of metastatic castration-resistant prostate cancer and Lutathera (177Lu-oxodotreotide) for inoperable or metastati…
metastatic castration-resistant prostate cancerprostate cancerTCEstargeted treatments
…have demonstrated promising clinical responses in patients with metastatic castration-resistant prostate cancer and have advanced into phase 3 clinical trials. Here we provide…
mCRPCsolid tumorsmetastatic castration-resistant prostate cancer
…ty in vivo, supporting potential development as a treatment for mCRPC.…
metastatic castration-resistant prostate cancermetastatic castration-resistant prostate cancer (mCRPC)mCRPC177Lu-PSMA-617cyclophosphamideCyRPTNCT03873805
…, Pachter L, Forman SJ, Priceman SJ. PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2024 Jun;30(6):1636-1644.Kostopoulos…
RCCccRCCprostate cancer
…rs targeting CD70 show early promising results for their use in RCC in preclinical and clinical trials. However, further research a…